Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma
1998

Interleukin 6 and Clinical Parameters in Malignant Pleural Mesothelioma

Sample size: 25 publication Evidence: moderate

Author Information

Author(s): T Nakano, AP Chahinian, M Shinjo, A Tonomura, M Miyake, N Togawa, K Ninomiya, K Higashino

Primary Institution: Hyogo College of Medicine

Hypothesis

What is the relationship between interleukin 6 levels and clinical parameters in patients with malignant pleural mesothelioma?

Conclusion

Malignant mesothelioma patients have high levels of interleukin 6 in pleural fluid that leak into the systemic circulation and induce clinical inflammatory reactions.

Supporting Evidence

  • Serum levels of interleukin 6 were significantly higher in mesothelioma than in lung adenocarcinoma.
  • 48% of mesothelioma patients exhibited thrombocytosis.
  • IL-6 levels in pleural fluid were significantly higher in mesothelioma patients compared to those with adenocarcinoma.

Takeaway

This study found that patients with a type of lung cancer called malignant pleural mesothelioma have a lot of a substance called interleukin 6 in their body, which can cause inflammation.

Methodology

Serum and pleural fluid samples were obtained from patients and analyzed for interleukin 6 and other proteins using ELISA kits.

Limitations

The study does not establish a specific diagnostic criterion for differentiating mesothelioma from adenocarcinoma.

Participant Demographics

25 patients with malignant pleural mesothelioma, 17 with lung adenocarcinoma, and 15 with tuberculous pleurisy.

Statistical Information

P-Value

p<0.01

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication